Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.

中文翻译：

---

获取用于晚期肺癌诊断和综合生物标志物测试的组织：国家肺癌圆桌会议最佳实践指南

针对非小细胞肺癌 (NSCLC) 患者的生物标志物驱动疗法的进展既为改善患者治疗（从而改善结果）提供了机会，也为公平的护理提供带来了新的挑战。在过去的十年中，新的生物标志物驱动疗法的持续开发及其使用适应症的不断变化，增强了跨学科沟通和协调对于肺癌患者或疑似肺癌患者的重要性。多学科团队面临着完成全面、及时的生物标志物测试以及针对复杂且时间敏感的疾病不断发展的证据基础的挑战。本指南提供了 NSCLC 综合生物标志物检测现状的背景信息，